University of California, Los Angeles
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, Los Angeles sits in the top decile of US sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count).
University of California, Los Angeles: 897 sponsored US clinical trials, 158 recruiting.
University of California, Los Angeles sponsors 897 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 622 completed. 98 of these trials are in Phase 3-4 (later-stage) and 194 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 17 trials.
Top-decile sponsor footprint
University of California, Los Angeles ranks in the top decile of sponsors by registered trial count (#37 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
622 of 679 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
897 total, page 12 of 18
Is MyPlate Approach to Helping Overweight Patients Lose Weight More Patient-centered?
NCT02514889
Arterial Inflammation and E-Cigarettes
NCT02734888
Walnut Consumption and Diabetes Risk
NCT03224533
A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program
NCT02384109
Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
NCT02110264
Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections
NCT03464279
Development of a Novel Biomarker for Liver Fibrosis
NCT02348814
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
NCT02396576
Trigeminal Nerve Stimulation for ADHD
NCT02155608
E-Cigarettes and SNA
NCT02724241
The Effect of Fruit/Vegetable Drinks on the Human Intestine
NCT02377063
The Cirrhosis Outpatient Optimization, Readmission & Safety Study
NCT02457988
Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening
NCT02495025
Endotracheal Tube Holder and Bite Guard Research
NCT02347488
Oxytocin and Learning for Teaching
NCT02393443
Oxytocin and the Social Brain
NCT02393456
Homeless Female Offenders Returning to the Community
NCT02258425
Vasopressin and the Social Brain
NCT02394054
Four-week Open-trial Extension TNS for ADHD
NCT03870737
Heart and Lung Function Monitoring System
NCT02168049
Trial to Reduce Hospitalizations in Children With Medical Complexity
NCT02277327
Culturally Tailoring a Stroke Intervention in Community Senior Centers
NCT02181062
Improving Cognition in Schizophrenia Using tDCS
NCT02539797
Sleep Health, Inflammation, and Emotion Study
NCT02270619
Non-invasive Intervention for Apnea of Prematurity
NCT02641249
Linking Families Together Study- A Randomized Trial to Raise Parental Monitoring
NCT02129153
Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab
NCT01717859
PTSD Affect Labeling Study
NCT05924399
Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York
NCT02227186
Comparing the Effect of Whey and Soy Protein on the Absorption of Pomegranate Polyphenols in the Human Body
NCT02233478
Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure
NCT02227316
Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use
NCT02603471
A System for Preference Assessment in Mental Health
NCT02183844
Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders
NCT02097563
Biomarkers of Fast Acting Therapies in Major Depression
NCT02165449
Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function
NCT02091219
A Physical Therapy Program Targeting Lower Extremity Selective Motor Control in Children With Spastic Cerebral Palsy
NCT07310550
Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents
NCT02134431
Neuromodulation for Post-Traumatic Stress Disorder
NCT02377089
FORE-SIGHT Tissue Oximeter During Cardiac Surgery
NCT02426268
Effect of Walnuts on Sperm Parameters and Male Fertility
NCT01954498
Waterproof Casting for Pediatric Distal Radius Fractures
NCT02095106
The SUCCEED Trial of Secondary Stroke Prevention
NCT01763203
Development of Ivermectin for Alcohol Use Disorders
NCT02046200
Study of Pomegranate Juice on Memory in Older Adults
NCT02093130
Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder
NCT02129790
Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot
NCT01990222
A Pilot Dosing and Timing Study to Optimize Imaging When Utilizing Endoscopic Fluorescence Imaging System During Laparoscopic Biliary and Hepatic Operations
NCT02070068
Naltrexone for Individuals of East Asian Descent
NCT02026011
Development of Ibudilast for Alcohol Use Disorder
NCT02025998
What is open in the University of California, Los Angeles pipeline
158 recruiting of 897 indexed (18% open); 622 completed (69%).
Phase mix: 98 late (III/IV) vs 194 early (I/II) (early-phase heavy).
Top condition: Depression (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, Los Angeles: open-pipeline peers nationwide
Peers matched on 897 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of California, Los Angeles sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 897 trials (± recruiting share)
- Indiana University · 890 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- ConvaTec · 18% recruiting · 17 trials
- Endologix · 18% recruiting · 17 trials
- National Institute on Deafness and Other Communication Disorders (NIDCD) · 18% recruiting · 34 trials
- NICHD Pelvic Floor Disorders Network · 18% recruiting · 17 trials
Related
What to do with this University of California, Los Angeles page
897 registered trials is a research-attention snapshot, not an endorsement of University of California, Los Angeles or any single study.
- 158 of University of California, Los Angeles's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of California, Los Angeles studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Los Angeles pipeline card: 897 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.